Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Employee compensation and benefits

Similar metrics at other companies

Lowe's Companies logo
LOWReportable Segment — Employee compensation and benefits
13.4%-0.1pp
Asset Entities logo
ASSTCorporate & Other — Employee compensation and benefits
$6.58M
Asset Entities logo
ASSTMedical Device — Employee compensation and benefits
$5.18M
Beneficient logo
BENFBen Custody — Employee compensation and benefits
$650K+121%
Beneficient logo
BENFBen Liquidity — Employee compensation and benefits
$464K+31.4%
Houlihan Lokey logo
HLIFinancial Restructuring — Employee compensation and benefits
$70.69M-20.8%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026 / Affordable MedicinesThree Months Ended June 30, 2026 / SpecialtyThree Months Ended June 30, 2025 / Affordable MedicinesThree Months Ended June 30, 2025 / Specialty
Employee compensation and benefits$12,016$1,326$14,693$1,279
Materials and supplies8,7961,0228,108450
Product development and studies (1)(89)2,6157562,371
In-licensing and upfront milestones3,5006,350
Facilities costs1,479301,793735
Regulatory fees1,3342,932
Other (2)5,9871,0017,2671,230
Total$33,023$5,994$41,899$6,065

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s affordable medicines — employee compensation and benefits?
Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — employee compensation and benefits of $12.02M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s affordable medicines — employee compensation and benefits changed year-over-year?
Amneal Pharmaceuticals, Inc.'s affordable medicines — employee compensation and benefits decreased by 18.2% year-over-year, from $14.69M to $12.02M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — employee compensation and benefits?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — employee compensation and benefits has grown at a 1.5% compound annual growth rate (CAGR), from $51.95M to $54.37M.
What does affordable medicines — employee compensation and benefits mean?
Reflects the total personnel-related costs, including salaries, bonuses, and benefits, allocated to the segment. Monitoring this helps evaluate labor efficiency and the cost structure required to support segment operations.

Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — employee compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude